Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
The regulatory decision follows promising results from RIVER-81
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
The safety profile was described as manageable, though not without notable toxicities
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The approval is supported by results from the Phase 3 SWOG 1826 trial
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
